Ozempic 2025 Sales Manager. Novo nordisk’s leading drug ozempic (semaglutide) is forecast to demonstrate a growth of 23% in its sales to $12.5 billion in 2023, consolidating its position as the dominant. Ozempic, with $8.3 billion in sales, is the leading novo nordisk product, accounting for 38.3% of the company’s total sales in 2022.

Novo nordisk’s leading drug ozempic (semaglutide) is forecast to demonstrate a growth of 23% in its sales to $12.5 billion in 2023, consolidating its position as the dominant. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected.